These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17433672)

  • 1. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
    Biftu T; Scapin G; Singh S; Feng D; Becker JW; Eiermann G; He H; Lyons K; Patel S; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Doss GA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3384-7. PubMed ID: 17433672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
    Herman GA; Bergman A; Liu F; Stevens C; Wang AQ; Zeng W; Chen L; Snyder K; Hilliard D; Tanen M; Tanaka W; Meehan AG; Lasseter K; Dilzer S; Blum R; Wagner JA
    J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
    J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).
    Kim D; Kowalchick JE; Edmondson SD; Mastracchio A; Xu J; Eiermann GJ; Leiting B; Wu JK; Pryor KD; Patel RA; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3373-7. PubMed ID: 17434732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design.
    Liang GB; Qian X; Biftu T; Singh S; Gao YD; Scapin G; Patel S; Leiting B; Patel R; Wu J; Zhang X; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2008 Jul; 18(13):3706-10. PubMed ID: 18524582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Biftu T; Feng D; Qian X; Liang GB; Kieczykowski G; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Scapin G; Patel S; Gao YD; Singh S; Wu J; Zhang X; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jan; 17(1):49-52. PubMed ID: 17055272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV.
    Oefner C; Pierau S; Schulz H; Dale GE
    Acta Crystallogr D Biol Crystallogr; 2007 Sep; 63(Pt 9):975-81. PubMed ID: 17704566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
    Madar DJ; Kopecka H; Pireh D; Yong H; Pei Z; Li X; Wiedeman PE; Djuric SW; Von Geldern TW; Fickes MG; Bhagavatula L; McDermott T; Wittenberger S; Richards SJ; Longenecker KL; Stewart KD; Lubben TH; Ballaron SJ; Stashko MA; Long MA; Wells H; Zinker BA; Mika AK; Beno DW; Kempf-Grote AJ; Polakowski J; Segreti J; Reinhart GA; Fryer RM; Sham HL; Trevillyan JM
    J Med Chem; 2006 Oct; 49(21):6416-20. PubMed ID: 17034148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors.
    Gao YD; Feng D; Sheridan RP; Scapin G; Patel SB; Wu JK; Zhang X; Sinha-Roy R; Thornberry NA; Weber AE; Biftu T
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3877-9. PubMed ID: 17502141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; McClure LD; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soeller WC; Soglia CB; Treadway JL; VanVolkenburg MA; Wang H; Wilder DC; Olson TV
    J Med Chem; 2006 Jun; 49(11):3068-76. PubMed ID: 16722626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity.
    Rigolet P; Xi XG; Rety S; Chich JF
    FEBS J; 2005 Apr; 272(8):2050-9. PubMed ID: 15819895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.
    Kim D; Kowalchick JE; Brockunier LL; Parmee ER; Eiermann GJ; Fisher MH; He H; Leiting B; Lyons K; Scapin G; Patel SB; Petrov A; Pryor KD; Roy RS; Wu JK; Zhang X; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
    J Med Chem; 2008 Feb; 51(3):589-602. PubMed ID: 18201067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.
    Terasaka T; Okumura H; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Seki N; Naoe Y; Inoue T; Tanaka K; Nakamura K
    J Med Chem; 2004 May; 47(11):2728-31. PubMed ID: 15139750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
    Mistry GC; Bergman AJ; Luo WL; Cilissen C; Haazen W; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
    J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.
    Kowalchick JE; Leiting B; Pryor KD; Marsilio F; Wu JK; He H; Lyons KA; Eiermann GJ; Petrov A; Scapin G; Patel RA; Thornberry NA; Weber AE; Kim D
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5934-9. PubMed ID: 17827003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.